share_log

Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

摩根士丹利将Esperion Therapeutics上调至同等权重,宣布目标价为9美元
Benzinga Real-time News ·  2023/02/03 06:23

Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.

摩根士丹利分析师Jeffrey Hung将Esperion Treateutics(纳斯达克:ESPR)的评级从减持上调至持平,并宣布目标价为9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发